Stephanie Van Kats
About Stephanie Van Kats
Stephanie Van Kats is the Business Unit Director of Innovative Medicines at Bristol Myers Squibb in Utrecht, Netherlands. She has extensive experience in neurology, hematology, and immuno-oncology, and has led the launch of multiple innovative medicines in the Netherlands.
Company
Stephanie Van Kats is currently working at Bristol Myers Squibb as the Business Unit Director Innovative Medicines. The company is located in Utrecht, Netherlands. Bristol Myers Squibb is a global biopharmaceutical company known for its mission to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.
Title
As the Business Unit Director Innovative Medicines, Stephanie Van Kats holds a pivotal role at Bristol Myers Squibb. In this capacity, she is responsible for overseeing the strategic direction and execution of initiatives related to innovative medicines in the Netherlands. Her role includes leading teams, driving product launches, and ensuring the successful penetration of new treatments into the market.
Career Background at Bristol Myers Squibb
Stephanie's career at Bristol Myers Squibb encompasses various roles, including Marketing & Sales Manager Neurology, Hematology Lead/Customer Marketing Manager Hematology and Immuno-Oncology Head & Neck/Glioblastoma, and Customer Marketing Manager - Multiple Myeloma. Additionally, she has served as the External Partnership Manager Hematology and the Targeting & Field Force Incentive Manager BeNeLux. Her diverse experience within the company highlights her versatility and depth of knowledge in different therapeutic areas. She also contributed as a Digital Strategy Associate and Member of the Works Council, further showcasing her multifaceted expertise.
Education and Expertise
Stephanie Van Kats has a comprehensive educational background. She studied at Utrecht University from 1999 to 2005 and continued her education at the NCOI Business School from 2007 to 2010. Additionally, she achieved the NIMA B certification from the Nederlands Instituut voor Marketing in 2018. Her educational pursuits have equipped her with strong foundations in business, marketing, and strategy, which she applies in her leadership role at Bristol Myers Squibb.
Key Initiatives and Contributions
During her tenure at Bristol Myers Squibb, Stephanie has led the launch of multiple innovative medicines in the Netherlands. Her efforts have significantly impacted patient care through the introduction of new treatments. She has extensive experience in neurology, hematology, and immuno-oncology, and has been instrumental in managing various therapeutic areas. Additionally, Stephanie played a crucial role in establishing external partnerships in hematology, enhancing collaborative efforts in the field. As the chair of the Works Council for eight years, she advocated for employee interests, demonstrating her commitment to organizational well-being.